Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted EPS (Basic) of -$0.67 for Q4 2025, down 369.11% on a QoQ basis from -$0.14 in Q3 2025, and down 1277.97% year-over-year from $0.06 in Q4 2024.
Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's EPS (Basic) history runs 2 years deep, the most recent figure standing at -$0.67 for Q4 2025.
- Quarterly EPS (Basic) fell 1277.97% year-over-year to -$0.67 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.12 (down 503.57% YoY) and the FY2025 annual result came in at -$1.33, down 334.93% from the prior year.
- EPS (Basic) was -$0.67 for Q4 2025 at Apimeds Pharmaceuticals US, down from -$0.14 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.04 in Q1 2024 and bottomed at -$0.67 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 0.32 |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 1.42 |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -1.49 |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 6.32 |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 0.15 |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1.97 |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 0.11 |
| 10 | Apimeds Pharmaceuticals US | 61.48 Mn | 61.48 Mn | - | -0.67 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.67 |
| Sep 30, 2025 | -0.14 |
| Jun 30, 2025 | -0.26 |
| Mar 31, 2025 | -0.05 |
| Dec 31, 2024 | -0.05 |
| Sep 30, 2024 | -0.04 |
| Jun 30, 2024 | -0.06 |
| Mar 31, 2024 | -0.04 |